A virus that has been specifically designed by scientists to be safe to normal tissue but deadly to cancer is showing early promise in a preliminary study, researchers said at the ESMO Conference Lugano (ECLU), Switzerland.
The
virus, called NV1020, is a type of
herpes simplex virus modified so that it selectively replicates in virus cells, killing them in the process.
"It doesn't replicate in normal, healthy cells, so our hope is that it will help fight cancers without causing side-effects in the rest of the body," said Dr. Axel Mescheder, VP Clinical Research & Development, from the Munich-based biotech company MediGene. The study is conducted in seven leading US-cancer centers, with Dr. Tony Reid from the University of California in San Diego, CA as Principal Investigator. Dr. Mescheder presented preliminary safety and efficacy results and a case report from this ongoing clinical trial in patients with colorectal cancer metastatic to the liver at the meeting.
Dr. Mescheder's poster presentation described the case of a patient whose cancer had spread to 10 different places around the liver and four in the lungs. He was given the virus treatment in four weekly infusions direct into blood stream, followed by two cycles of approved chemotherapy.
Six months after treatment, scans showed the liver masses had nearly disappeared."The reduction in the tumor masses was really impressive in this patient," Dr. Mescheder said."The hepatic masses almost disappeared."
The patient survived for 12 months after treatment.